Abstract
Epidemiology of benign prostatic hyperplasia (BPH) is incompletely understood. The following study was done to estimate the prevalence of BPH according to obstructive and irritative symptoms of prostate obstruction determined by uroflowmetry and prostate size. In a cross-sectional study a total of 8,466 men aged 40 or older were interviewed by 74 general practitioners and answered the International Prostate Symptom Score (I-PSS) questionnaire. The subjects were randomly identified from 30 counties of Iran. They were invited to have a digital rectal examination (DRE), serum total prostate-specific antigen (tPSA) assay, abdominal ultrasonography to measure prostate size and measurement of maximum urinary flow rate (Qmax). Data on medical history, toxic habits, and current use of medications were obtained. Of the men interviewed, the prevalence of BPH, defined as I-PSS greater than 7, maximum flow less than 15 ml/s and prostate size greater than 30 gm, was 23.8%. The prevalence increased with age, from 1.2% in men 40–49 to 36% in those >70 years (tested for trend, P = 0.001). A positive association was found between BPH and body mass index (BMI) (P = 0.04), height (P = 0.03), diabetes mellitus (P = 0.04), increased total energy intake (P = 0.02), age-adjusted levels of total PSA (P = 0.02), heart disease (P = 0.03), and marital status (P = 0.01). The prevalence of BPH is relatively high in Iran. The provided bothersome due to BPH did not correlate to symptom severity and should be considered independently in clinical decision-making.
Similar content being viewed by others
References
Berry SJ, Coffey DS, Walsh PC et al (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479
Roehrborn CG, McConnell JD (2002) Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds) Campbell’s urology, 8th edn. WB Saunders Co, Philadelphia, pp 1297–1336
Barry MJ, Beckley S, Boyle P et al (1992) Importance of understanding the epidemiology and natural history of BHP. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds) Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, 26–27 June, 1991. S. C. I., Paris, pp 13–21
Chute CG, Panser LA, Girman CJ et al (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150:85–89
Tsukamoto T, Kumamoto Y, Masumori N et al (1995) Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 154:391–395
Bosch JL, Hop WC, Kirkels WJ et al (1995) The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 75:622–630
Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471
Jacobsen SJ, Girman CJ, Guess HA et al (1995) New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 155:477–481
Fay R (1985) Prostate obstruction in Chinese population. In: Hinman F Jr (ed) Benign prostatic hyperplasia. Springer, Berlin Heidelberg New York, pp 26–29
McConnell JD (1997) Epidemiology, etiology, pathophysiology and diagnosis of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Stamey TA, Vaughan SD Jr (eds) Campbell’s urology, 7th edn. WB Saunders Co, Philadelphia, pp 1429–1452
Choi J, Ikeguchi EF, Lee SW (2002) Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index? Eur Urol 42:7–11
Barry MJ, Williford WO, Chang Y et al (1995) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154:1770–1774
Napalkov P, Maisonneuve P, Boyle P (1995) Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46:47–55
Stephenson WP, Chute CG, Guess HA et al (1991) Incidence and outcome of surgery for benign prostatic hyperplasia among residents of Rochester, Minnesota: 1980–87. A population-based study. Urology 38:32–42
Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173:1256–1261
Tan HY, Choo WC, Archibald C et al (1997) A community-based study of prostatic symptoms in Singapore. J Urol 157:890–893
Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ et al (1998) Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 159:878–882
Ozturk A, Serel TA, Kosar A et al (2000) Prevalence of benign hypertrophy of the prostate in Turkish men hospitalized in urology. Prog Urol 10:568–570
Garraway WM, Russel EB, Lee RJ et al (1993) Impact of previously unrecognized benign prostatic hyperplasia on the lives of middle-aged and elderly men. Br J Gen Pract 43:318–321
Roberts R, Tsukamoto T, Kumamoto Y et al (1997) Association between cigarette smoking and prostatism in a Japanese community. Prostate 30:154–159
Meigs JB, Mohr B, Barry MJ et al (2001) Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54:935–944
Giovannucci E, Rimm EB, Chute CG et al (1994) Obesity and benign prostatic hyperplasia. Am J Epidemiol 140:989–1002
Parsons JK, Carter HB, Partin AW et al (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91:2562–2568
Acknowledgments
Many physicians, coordinators, project managers, secretaries, and data reviewers assisted in this study. I would like to thank all of them. The collection of data was made possible by the whole-hearted collaboration of the 74 general practitioners. Many thanks are due to for the nationwide financial support of the Iranian people. Certainly without this financial support, performing this study would have not been possible. Mrs. Nayyer Shafiei reviewed the medical records, Dr. Alireza Khoshdel provided preliminary analysis of these data, and Saba Safarinejad assisted in the preparation of the manuscript. The interpretation and reporting of these data are the responsibility of the author and in no way should be seen as an official policy or interpretation of the Iranian government.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Safarinejad, M.R. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol 40, 921–931 (2008). https://doi.org/10.1007/s11255-008-9338-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-008-9338-7